中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系

李品桦 刘旭东 黄露 朱沪敏 吴铁雄 庞华珍

李品桦, 刘旭东, 黄露, 等. 非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系[J]. 临床肝胆病杂志, 2021, 37(11): 2558-2562. DOI: 10.3969/j.issn.1001-5256.2021.11.015
引用本文: 李品桦, 刘旭东, 黄露, 等. 非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系[J]. 临床肝胆病杂志, 2021, 37(11): 2558-2562. DOI: 10.3969/j.issn.1001-5256.2021.11.015
LI PH, LIU XD, HUANG L, et al. Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(11): 2558-2562. DOI: 10.3969/j.issn.1001-5256.2021.11.015
Citation: LI PH, LIU XD, HUANG L, et al. Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(11): 2558-2562. DOI: 10.3969/j.issn.1001-5256.2021.11.015

非酒精性脂肪性肝病肝纤维化进展与内皮素-1/一氧化氮的关系

DOI: 10.3969/j.issn.1001-5256.2021.11.015
基金项目: 

广西科学基金项目 AB18221009

广西中医药大学岐黄工程高层次人才团队培育项目 2021007

2019年广西一流学科建设课题 2019XK139

2019年中医药传承与创新人才培养平台建设项目 National Traditional Chinese Medicine Education Letter No.41, 2019

国家自然科学基金 81473532

详细信息
    通讯作者:

    刘旭东,lxdlhx@163.com

  • 中图分类号: R575.2; R575.5

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease

Research funding: 

Guangxi Science Foundation Project AB18221009

High-Level Talent Team Cultivation Project of the Qihuang Project of Guangxi University of Traditional Chinese Medicine 2021007

Guangxi First-Class Discipline Construction Project in 2019 2019XK139

Traditional Chinese Medicine Inheritance and Innovation Talents Training Platform Construction Project in 2019 National Traditional Chinese Medicine Education Letter No.41, 2019

National Natural Science Foundation of China 81473532

  • 摘要:   目的  探讨非酒精性脂肪性肝病(NAFLD)肝纤维化进展是否会对内皮功能产生影响,以早期发现纤维化进展对内皮功能障碍所致心血管疾病的预警。  方法  选取2019年4月—2020年10月就诊于广西中医药大学附属瑞康医院肝病科门诊/住院,经超声诊断为脂肪肝且符合NAFLD诊断标准的患者280例,收集并记录患者的一般资料及各血清学指标。对超声诊断的NAFLD患者进行FibroTouch技术检测,分别记录其脂肪衰减度(FAP)及肝硬度值(LSM),根据LSM将研究对象分为非进展期纤维化组(LSM<11 kPa,n=239) 和进展期纤维化组(LSM≥11 kPa,n=41),比较分析NAFLD肝纤维化进展与内皮素-1(ET-1)、一氧化氮(NO)的关系。计量资料两组间比较采用t检验或Mann-Whitney U检验,相关性分析用Spearman分析方法。  结果  非进展期纤维化组和进展期纤维化组中ET-1(Z=-0.190, P=0.849)、NO(Z=-1.509, P=0.131)的表达水平比较差异无统计学意义。BMI、ALT、AST、GGT、TG、HDL-C在两组间比较差异均有统计学意义(Z值分别为-3.977、-4.162、-3.471、-3.201、-3.202、-3.311,P值均<0.05)。Spearman分析示,LSM与ET-1、NO、NO/ET-1无相关性(rs值分别为-0.046、0.086和0.104,P值均>0.05)。进一步分析了ET-1、NO与血脂、肝功能等指标的相关性,结果显示ET-1与年龄、NO、ALT、AST、GGT、TC、TG、HDL-C、LDL-C、FAP、BMI均不相关(P值均>0.05),NO与年龄、ET-1、ALT、AST、GGT、TC、TG、HDL-C、LDL-C、FAP、BMI各指标间也并无相关性(P值均>0.05)。  结论  在本研究中,NAFLD肝纤维化进展对ET-1、NO无影响,提示纤维化进展可能对内皮功能无影响。

     

  • 表  1  两组NAFLD患者ET-1、NO等血清学指标及一般资料比较

    指标 非进展期纤维化组
    (n=239)
    进展期纤维化组
    (n=41)
    统计值 P
    年龄(岁) 46.80±12.27 47.39±13.16 t=-0.280 0.577
    NO(μmol/L) 36.65(23.47~55.06) 43.96(33.25~57.66) Z=-1.509 0.131
    ET-1(pg/mL) 56.41(39.10~77.17) 57.71(39.98~73.49) Z=-0.190 0.849
    ALT(U/L) 26(18~39) 46(31~77) Z=-4.162 <0.001
    AST(U/L) 24(18~32) 34(22~61) Z=-3.471 0.001
    GGT(U/L) 36(25~56) 47(35~77) Z=-3.201 0.001
    TC(mmol/L) 5.00±1.04 4.70±1.31 t=1.601 0.083
    TG(mmol/L) 1.78(1.26~2.61) 1.29(0.92~1.82) Z=-3.202 0.001
    HDL-C(mmol/L) 1.13(1.00~1.35) 0.97(0.81~1.17) Z=-3.311 0.001
    LDL-C(mmol/L) 2.87±0.89 2.78±0.93 t=0.639 0.725
    FAP(db/m) 258.56±36.98 272.90±36.55 t=-2.297 0.552
    BMI(kg/m2) 26.39(24.44~28.69) 27.39(26.27~31.51) Z=-3.977 <0.001
    NO/ET-1 0.70(0.43~1.05) 0.75(0.54~1.18) Z=-1.291 0.197
    下载: 导出CSV

    表  2  ET-1、NO及NO/ET-1与LSM的相关性分析

    指标 rs P
    NO 0.086 0.153
    ET-1 -0.046 0.443
    NO/ET-1 0.104 0.082
    下载: 导出CSV

    表  3  ET-1与各指标的相关性分析

    指标 ET-1 NO
    rs P rs P
    年龄 -0.017 0.771 0.004 0.941
    NO/ET-1 0.054 0.369 0.054 0.369
    ALT -0.067 0.265 0.011 0.860
    AST -0.016 0.788 0.052 0.383
    GGT -0.031 0.603 0.004 0.951
    TC 0.004 0.952 -0.051 0.399
    TG 0.051 0.394 -0.052 0.389
    HDL-C -0.084 0.162 -0.012 0.729
    LDL-C -0.030 0.620 -0.076 0.205
    FAP 0.080 0.180 -0.013 0.832
    BMI 0.044 0.466 -0.021 0.729
    下载: 导出CSV
  • [1] MIKOLASEVIC I, ORLIC L, FRANJIC N, et al. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-Where do we stand?[J]. World J Gastroenterol, 2016, 22(32): 7236-7251. DOI: 10.3748/wjg.v22.i32.7236.
    [2] VILLANOVA N, MOSCATIELLO S, RAMILLI S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease[J]. Hepatology, 2005, 42(2): 473-480. DOI: 10.1002/hep.20781.
    [3] CHU WW, GUAN LL, HUANG DH, et al. Correlation between plasma endothlin-1 level and insulin resistance in impaired glucose regulation patients with nonalcoholic fatty liver disease[J]. Zhejiang Med J, 2018, 40(6): 600-602. DOI: 10.12056/j.issn.1006-2785.2018.40.6.2016-2083.

    褚韦韦, 官莉莉, 黄迪华, 等. 糖调节异常合并非酒精性脂肪性肝病患者血内皮素-1与胰岛素抵抗的相关性研究[J]. 浙江医学, 2018, 40(6): 600-602. DOI: 10.12056/j.issn.1006-2785.2018.40.6.2016-2083.
    [4] DINH QN, DRUMMOND GR, SOBEY CG, et al. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension[J]. Biomed Res Int, 2014, 2014: 406960. DOI: 10.1155/2014/406960.
    [5] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm

    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm
    [6] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [7] ZHU HM, WANG QY. Advances in the diagnosis and treatment of nonalcoholic fatty liver disease-related liver fibrosis[J]. J Clin Hepatol, 2020, 36(1): 178-181. DOI: 10.3969/j.issn.1001-5256.2020.01.042.

    朱红梅, 王勤英. 非酒精性脂肪性肝病肝纤维化的诊断和治疗进展[J]. 临床肝胆病杂志, 2020, 36(1): 178-181. DOI: 10.3969/j.issn.1001-5256.2020.01.042.
    [8] JIANG YZ, NIE HM, WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.

    姜煜资, 聂红明, 汪蓉. 非酒精性脂肪性肝病的发病机制[J]. 临床肝胆病杂志, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.
    [9] BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): s47-s64. DOI: 10.1016/j.jhep.2014.12.012.
    [10] WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.

    王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
    [11] ANSTEE QM, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 425-439. DOI: 10.1038/s41575-018-0010-0.
    [12] HENSON JB, SIMON TG, KAPLAN A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2020, 51(7): 728-736. DOI: 10.1111/apt.15660.
    [13] DEGERTEKIN B, OZENIRLER S, ELBEG S, et al. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis[J]. Dig Dis Sci, 2007, 52(10): 2622-2628. DOI: 10.1007/s10620-006-9147-8.
    [14] KARDUM D, FABIJANIĆ D, LUKIĆ A, et al. Correlation of endothelin-1 concentration and angiotensin-converting enzyme activity with the staging of liver fibrosis[J]. Coll Antropol, 2012, 36(2): 413-418. DOI: 10.1016/j.anthro.2012.05.004.
    [15] IWAKIRI Y, KIM MY. Nitric oxide in liver diseases[J]. Trends Pharmacol Sci, 2015, 36(8): 524-536. DOI: 10.1016/j.tips.2015.05.001.
    [16] TSOCHATZIS EA, NEWSOME PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care[J]. Lancet Gastroenterol Hepatol, 2018, 3(7): 509-517. DOI: 10.1016/S2468-1253(18)30077-3.
  • 加载中
表(3)
计量
  • 文章访问数:  110
  • HTML全文浏览量:  30
  • PDF下载量:  29
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-13
  • 录用日期:  2021-04-25
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回